KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Minority Interest (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Minority Interest for 17 consecutive years, with $641.0 million as the latest value for Q4 2025.

  • Quarterly Minority Interest rose 170.46% to $641.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $641.0 million through Dec 2025, up 170.46% year-over-year, with the annual reading at $641.0 million for FY2025, 170.46% up from the prior year.
  • Minority Interest hit $641.0 million in Q4 2025 for Abbott Laboratories, up from $310.0 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $641.0 million in Q4 2025 to a low of $209.0 million in Q3 2022.
  • Historically, Minority Interest has averaged $253.9 million across 5 years, with a median of $229.5 million in 2021.
  • Biggest five-year swings in Minority Interest: dropped 3.48% in 2023 and later soared 170.46% in 2025.
  • Year by year, Minority Interest stood at $222.0 million in 2021, then fell by 1.35% to $219.0 million in 2022, then grew by 2.28% to $224.0 million in 2023, then increased by 5.8% to $237.0 million in 2024, then skyrocketed by 170.46% to $641.0 million in 2025.
  • Business Quant data shows Minority Interest for ABT at $641.0 million in Q4 2025, $310.0 million in Q3 2025, and $264.0 million in Q2 2025.